Molecular Formula | C5H6O4 |
Molar Mass | 130.1 |
Density | 1.37 g/cm3 |
Melting Point | 144-145 °C (lit.) |
Boling Point | 250.0±23.0 °C(Predicted) |
Flash Point | 108.9°C |
Solubility | Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) |
Vapor Presure | 0.00706mmHg at 25°C |
Appearance | White solid |
Color | Off-White |
Maximum wavelength(λmax) | ['209nm(MeOH)(lit.)'] |
pKa | 3.40±0.10(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.468 |
MDL | MFCD00063174 |
Physical and Chemical Properties | Melting point 144-145°C |
Use | Used as a feed fungicide |
In vitro study | Monomethyl fumarate completely inhibits forskolin induced cAMP synthesis with an IC 50 of 70 nM. Monomethyl fumarate induces a dose-dependent Ca 2+ signal in GPR109A transfected cells with an EC 50 of 9.4 μM. Monomethyl fumarate (25 μM; 24 hours) attenuates 7β-OHC-induced cytotoxicity: cell growth inhibition; decreased cell viability; mitochondrial dysfunction; and cell death induction. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 41 - Risk of serious damage to eyes |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S39 - Wear eye / face protection. |
WGK Germany | 3 |
HS Code | 29171900 |
biological activity | Monomethyl Fumarate (MMF, Monomethylfumarate, Fumaric acid monomethyl ester, Methyl hydrogen fumarate) is an active metabolite of psoriasis drug Fumaderm and an effective GPR109A agonist. Monomethyl Fumarate can prevent the main dysfunction related to neurodegenerative diseases: oxidative stress, mitochondrial dysfunction, apoptosis and autophagy. |
Target | Value |
Animal Model: | Albino BALB/c mice (male, 6 weeks old) |
Dosage: | 50, 65, 75, 100 mg/kg |
Administration: | IP |
Result: | Prevented these morphologic changes (bright light exposure induced photoreceptor death) in a dose-dependent manner. |
Use | Used as a feed mold inhibitor |